Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising biomarker in the advancement of cancer management, including early diagnosis, screening, prognosis, identification of actionable targets, and serial tumor monitoring. The specific size pattern of DNA fragments derived from cancer cells is observed to differ from that of cfDNA fragments shed by non-cancer cells. Research into the physiological and biological properties of cfDNA reveals the molecular signature carried by each cfDNA fragments, which can reflect their tissue origins, as well as the mutational profiles with significant genetic alterations. Understanding the fragmentation and size distribution of cfDNA might be a valuable hotspot in liquid biopsy research, with the potential to drive innovation in oncology.

液体活检测试中的肿瘤特异性循环无细胞 DNA (cfDNA) 是一种新的有前途的生物标志物，可促进癌症管理，包括早期诊断、筛查、预后、可操作目标的识别和连续肿瘤监测。观察到源自癌细胞的 DNA 片段的特定大小模式与非癌细胞脱落的 cfDNA 片段不同。对 cfDNA 生理和生物学特性的研究揭示了每个 cfDNA 片段所携带的分子特征，这可以反映它们的组织来源，以及具有显着遗传改变的突变谱。了解 cfDNA 的片段化和大小分布可能是液体活检研究中的一个有价值的热点，具有推动肿瘤学创新的潜力。